plasma-derived FVIII/VWF concentrate
ApprovedSmall molecule
Grifols Therapeutics LLCplasma-derived FVIII/VWF concentrate is one of 24 small molecule programs targeting Von Willebrand disease. It is currently in Approved.
1
Indications
2
Total Trials
1
Active Trials
23
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
37 competitors in Von Willebrand Disease
#DrugCompanyPhaseTrials
1Cyklokapron
AAmring
Phase 3
Advate
TakedaPhase 3
Bypassing Agents
RochePhase 3
Biostate
CSL BehringPhase 3
plasma-derived FVIII/VWF concentrate
Grifols Therapeutics LLCApproved
Hemlibra
RochePhase 1
Recombinant Factor IX
BBaxalta now part of Shire
Phase 3
Wilate
OctapharmaPhase 3
Rfviii
UUniversity of Pittsburgh
Phase 3
Vonicog Alfa
TakedaPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Immune Tolerance1 trial
Safety/Efficacy Study to Assess Whether FVIII/VWF Concentrate Can Induce Immune Tolerance in Haemophilia A Patients
Unknown status·FFondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico·Phase 4·NCT02479087·20 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company